These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7370051)

  • 21. Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid.
    Odar-Cederlöf I; Borga O
    Clin Pharmacol Ther; 1976 Jul; 20(1):36-47. PubMed ID: 1277724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interference by diflunisal with the FETI method for serum thyroxine.
    Huisman JW
    Ann Clin Biochem; 1986 Mar; 23 ( Pt 2)():223-4. PubMed ID: 3532915
    [No Abstract]   [Full Text] [Related]  

  • 23. Species differences in protein binding of diflunisal.
    Lin JH
    Drug Metab Dispos; 1989; 17(2):221-3. PubMed ID: 2565215
    [No Abstract]   [Full Text] [Related]  

  • 24. Salicylate saturation index in neonatal jaundice.
    Seem E; Wille L
    Biol Neonate; 1975; 26(1-2):67-75. PubMed ID: 1148341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacological consequences of the binding of anti-rheumatic drugs to plasma proteins in the treatment of rheumatoid arthritis.
    McArthur JN
    Agents Actions; 1979 Jun; 9(2):212-6. PubMed ID: 382804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid high-performance liquid chromatographic method for the quantitative determination of diflunisal in plasma.
    Van Loenhout JW; Ketelaars HC; Gribnau FW; Van Ginneken CA; Tan Y
    J Chromatogr; 1980 Jun; 182(3-4):487-91. PubMed ID: 7391195
    [No Abstract]   [Full Text] [Related]  

  • 27. Circular dichroic investigations of the binding of salicylate and related compounds to human serum albumin.
    Otagiri M; Perrin JH
    Biochem Pharmacol; 1977 Feb; 26(4):283-8. PubMed ID: 849317
    [No Abstract]   [Full Text] [Related]  

  • 28. Thermodynamics of the binding of salicylate to human serum albumin: evidence of non-competition with imidazole.
    Matias I; Ceballos A; Gonzalez-Velasco F; Cachaza JM
    J Pharm Pharmacol; 1989 Feb; 41(2):123-5. PubMed ID: 2568420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid estimation of diflunisal in plasma and urine by high-performance liquid chromatography and a comparison with a fluorometric method.
    Balali-Mood M; King IS; Prescott LF
    J Chromatogr; 1982 Apr; 229(1):234-40. PubMed ID: 7085831
    [No Abstract]   [Full Text] [Related]  

  • 30. Aspects of multiple binding of anticoagulants and other drugs.
    Wosilait WD
    Gen Pharmacol; 1977; 8(1):7-12. PubMed ID: 590727
    [No Abstract]   [Full Text] [Related]  

  • 31. Steady-state disposition of diflunisal: once- versus twice-daily administration.
    Mojaverian P; Rocci ML; Swanson BN; Vlasses PH; Chremos AN; Lin JH; Yeh JC; Ferguson RK
    Pharmacotherapy; 1985; 5(6):336-9. PubMed ID: 3841206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inability to interpret toxic salicylate levels in patients taking aspirin and diflunisal.
    Adelman HM; Wallach PM; Flannery MT
    J Rheumatol; 1991 Apr; 18(4):522-3. PubMed ID: 2066942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of serum protein binding on pharmacokinetics and anticoagulant activity of phenprocoumon in rats.
    Trenk D; Jähnchen E
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):177-91. PubMed ID: 7431221
    [No Abstract]   [Full Text] [Related]  

  • 34. Plasma protein binding and interaction studies with piroxicam.
    Trnavská Z; Trnavský K
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Aug; 327(1):81-5. PubMed ID: 6493354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decrease of in vitro serum protein binding of salicylate in rheumatoid arthritis.
    Netter P; Monot C; Stalars MC; Mur JM; Royer RJ; Faure G; Pourel J; Martin J; Gaucher A
    Eur J Drug Metab Pharmacokinet; 1984; 9(2):109-16. PubMed ID: 6745302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma protein carbamylation and decreased acidic drug protein binding in uremia.
    Erill S; Calvo R; Carlos R
    Clin Pharmacol Ther; 1980 May; 27(5):612-8. PubMed ID: 7371359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased protein binding of salicylates in Kawasaki disease.
    Koren G; Silverman E; Sundel R; Edney P; Newburger JW; Klein J; Robieux I; Laxer R; Giesbrecht E; Burns JC
    J Pediatr; 1991 Mar; 118(3):456-9. PubMed ID: 1999792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacology of malnutrition. Part I. Salicylate binding studies using normal serum/plasma and kwashiorkor serum.
    Eyberg C; Moodley GP; Buchanan N
    S Afr Med J; 1974 Dec; 48(61):2564-7. PubMed ID: 4453937
    [No Abstract]   [Full Text] [Related]  

  • 39. The effect of bile salts on the binding of bilirubin by plasma proteins.
    Fulop M; Sandson J
    Clin Sci; 1967 Dec; 33(3):459-69. PubMed ID: 6082605
    [No Abstract]   [Full Text] [Related]  

  • 40. Reserve albumin binding capacity, salicylate saturation index, and red cell binding of bilirubin in neonatal jaundice.
    Bratlid D
    Arch Dis Child; 1973 May; 48(5):393-7. PubMed ID: 4703070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.